Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GLS | O94925 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10873457 | 0.89 | ATM (0.80) | ATMALDH1A1HPGDPOLBGLS | |
| SCHEMBL20266311 | 0.86 | ATM (0.74) | ATMALDH1A1HPGDPOLBMEN1 | |
| SCHEMBL2644442 | 0.82 | ALDH1A1 (1.00) | ATMALDH1A1HPGDPOLBHTT | |
| SCHEMBL26599232 | 0.81 | ATM (0.69) | ATMALDH1A1HPGDPOLBGLS | |
| SCHEMBL17967124 | 0.81 | ALDH1A1 (0.72) | ATMALDH1A1POLBGLSHTT | |
| SCHEMBL17967711 | 0.81 | ATM (0.69) | ATMALDH1A1HPGDPOLBGLS | |
| Hydrogen Sulfide SCHEMBL28084028 | 0.81 | ALDH1A1 (0.96) | ATMALDH1A1HPGDPOLBHTT | |
| Hydrochloric Acid SCHEMBL21391938 | 0.80 | ATM (0.67) | ATMALDH1A1HPGDPOLBGLS | |
| SCHEMBL11925831 | 0.80 | ATM (0.66) | ATMALDH1A1HPGDPOLBGLS | |
| SCHEMBL19793294 | 0.78 | ATM (0.63) | ATMALDH1A1HPGDPOLBGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658072-A4 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | claimed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | claimed |
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-10428061-B2 | Autotaxin inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3253748-B1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| CN-105263915-B | Glutamine enzyme inhibitor and application method | 安吉奥斯医药品有限公司 | 2019-04-12 | — | — | CN | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-4237136-A | IMMUNOSTIMULANTS | GRUNENTHAL GMBH (DE) | 1980-12-02 | — | — | US | disclosed |
| US-3919428-A | 2-Amino-5-(substituted or unsubstituted phenylalkyl)1,3,4-thiadiazoles for treating anxiety | SANDOZ AG | 1975-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | ENPP2, RNASE1, ATXN10 | ATM 3468/4885ALDH1A1 4116/4885HPGD 3090/4885 |
| US-10428061-B2 | Autotaxin inhibitors | ENPP2, ATXN10, RNASE1 | ATM 3535/4885ALDH1A1 4227/4885HPGD 3259/4885 |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, BACE1, PSEN1 | ATM 3523/4885ALDH1A1 2945/4885HPGD 2301/4885 |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | APP, BACE1, PSEN1 | ATM 3523/4885ALDH1A1 2945/4885HPGD 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.